ArticleKidney international reports2025
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Divergent Renal Benefits of Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Nondiabetic Kidney Disease.Kidney & blood pressure research · 2026Pooled it
- In Reply: Pseudo-Index Events cannot be Configured on the TriNetX Platform.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- SGLT2 inhibitors in autosomal dominant polycystic kidney disease: rationale, evidence gaps, and ongoing clinical trials.International urology and nephrology · 2026Review
- Review
- Empagliflozin in ADPKD with suspected IgA nephropathy: antiproteinuric response without adverse events.BMC nephrology · 2026Article
- SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis.Cureus · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: Mechanistic Insights and Therapeutic Promise.Journal of the American Society of Nephrology : JASN · 2026Review
- Real-World Outcomes of Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Nondiabetic Autosomal-Dominant Polycystic Kidney Disease: Effects on Progression to Dialysis in a TrinetX Cohort.Mayo Clinic proceedings. Innovations, quality & outcomes · 2026Article
- Progressive endocannabinoid system dysregulation in autosomal dominant polycystic kidney disease.Molecular medicine (Cambridge, Mass.) · 2026Article
- Sodium-Glucose Cotransporter-2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes.Kidney international reports · 2026Article
- Response to the Letter to the Editor Entitled "SGLT2 Inhibitors in ADPKD: Time to Integrate Cardiovascular Outcomes".Kidney international reports · 2026Article
- Zhenwu Decoction Attenuates Water-Retention-Related Phenotypes and Multiorgan Injury in Rats With Doxorubicin-Induced Chronic Heart Failure.Cardiovascular therapeutics · 2026Article
- An Observational Study of SGLT2 Inhibitors and Their Use in Autosomal Dominant Tubulointerstitial Kidney Disease.Research square · 2025Article
- Dapagliflozin use in tolvaptan-treated patients with ADPKD: exploring renal outcomes in a retrospective study.Clinical kidney journal · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, delays the progression of chronic kidney disease (CKD), its effect on patients with autosomal dominant polycystic kidney disease (ADPKD) has not been established. We conducted an open-label, randomized controlled crossover trial to evaluate the additive effects of dapagliflozin in patients with ADPKD receiving tolvaptan. Methods: A total of 27 patients were randomly counterbalanced to receive dapagliflozin 10 mg or usual care without dapagliflozin for 6 months. The primary endpoint was the slope of the estimated glomerular filtration rate (eGFR) determined by linear regression from 1 to 6 months, and the secondary endpoints included changes in total kidney volume (TKV). eGFR was calculated based on creatinine levels (eGFR Results: There were significant attenuations in the eGFR Conclusion: In patients with ADPKD treated with tolvaptan, dapagliflozin may have an additive effect in slowing ADPKD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.